Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T.

PubWeight™: 0.86‹?›

🔗 View Article (PMC 4160816)

Published in Prostate Cancer Prostatic Dis on June 24, 2014

Authors

E J Small1, C S Higano2, P W Kantoff3, J B Whitmore4, M W Frohlich4, D P Petrylak5

Author Affiliations

1: Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, CA, USA.
2: Departments of Oncology and Urology, School of Medicine, University of Washington, Seattle, WA, USA.
3: Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
4: Dendreon Corporation, Seattle, WA, USA.
5: Smilow Cancer Center, Yale University, New Haven, CT, USA.

Associated clinical trials:

Study of Immunotherapy to Treat Advanced Prostate Cancer | NCT00861614

Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer | NCT01057810

Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy | NCT00065442

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer (COMET-2) | NCT01522443

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | NCT00005947

Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer | NCT01133704